FEB 22 - 23 2017
Precision Medicine 2017
11 70 11656

Precision Medicine 2017 was a success and is now availabe On Demand!

Imagine receiving a full diagnosis from a simple blood test, or the ability to tailor the perfect treatment to your individual genetic makeup, taking into account your specific susceptibilities to side effects. What if we could apply a patient’s genetic information to gain insights into the genetic variations of diseases and expedite drug development, to create more precise therapies? This is the goal of Precision Medicine.

Following are the topics for this years Precision Medicine event:

  • Clinical Implementations of Precision Medicine
  • How Advancements are Shaping Precision Medicine
  • Precision Medicine Issues and Challenges
  • Precision Medicine for Drug Development
  • Precision Medicine Initiative


Precision Medicine 2017 will continue the dialogue and provide updates on the Precision Medicine Initiative ® (PMI), that called for initial funding of $215 million to support the creation of a national research cohort of 1 million or more U.S. volunteers (the PMI Cohort Program; $130 million), new efforts in cancer drug development ($70 million), advances in FDA regulatory structures ($10 million), and development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems through the ONC ($5 million).

Precision Medicine is becoming an integral part of research in the science community. The discipline not only involves individual genetic information, but also environmental, behavioral, and clinical data. A combination of these factors allows researchers to put together a comprehensive view of each patient that aids in their search for precision approaches to health maintenance, disease prevention, and therapies.

Continuing Education
By participating in this virtual event and watching webcast presentations, you can earn Free Continuing Education (CE) and/or Continuing Medical Education (CME) credits. To earn educational credits, you must view an entire presentation. Following the presentation you must click on the educational credit link provided for that particular speaker and follow the required process. Once you have completed the process, you will receive a certificate for the educational credit.

Use #LRprecisionmed to follow the conversation
 


Speakers:

Show Resources
Agenda
All times are Pacific Time
  • FEB 22, 2017 06:00 AM PST
    Speaker: Marc Williams, MD
  • FEB 22, 2017 06:00 AM PST
    Speaker: David Smith, PhD
  • FEB 22, 2017 07:30 AM PST
    Speaker: Laura Koontz, PhD
  • FEB 22, 2017 09:00 AM PST
    Speaker: Ruth Luna, PhD, MB (ASCP) CM
  • FEB 22, 2017 10:30 AM PST
    Speaker: Matt Nelson, PhD
  • FEB 22, 2017 10:30 AM PST
    Salim Essakali
    Associate Director, NGS
    Yi Kong, Ph.D.
    Product Director, QIAGEN
  • FEB 22, 2017 12:00 PM PST
    Speaker: Dexter Hadley, MD, PhD
  • FEB 22, 2017 12:00 PM PST
    Speaker: Carl Simon, PhD
  • FEB 22, 2017 01:30 PM PST
    Speaker: Sami Amr, PhD
  • FEB 23, 2017 06:00 AM PST
    Speaker: Matt Klusas
  • FEB 23, 2017 06:00 AM PST
    Speaker: Michael Nall
  • FEB 23, 2017 07:30 AM PST
    Speaker: Daniel Mueller, PhD
  • FEB 23, 2017 09:00 AM PST
    Speaker: John Ryals, PhD
  • FEB 23, 2017 10:30 AM PST
    Speaker: Erica Ramos, MS, CGC
  • FEB 23, 2017 12:00 PM PST
    Speaker: James Prudent, PhD
  • FEB 23, 2017 12:00 PM PST
    Speaker: Marty Tenenbaum, PhD
  • FEB 23, 2017 12:00 PM PST
    Speaker: Giacinto Scoles, PhD
  • FEB 23, 2017 01:30 PM PST
    Speaker: Nathan Price, PhD
  • Clinical Implementations of Precision Medicine
  • FEB 22, 2017 06:00 AM PST
    Speaker: Marc Williams, MD
  • FEB 23, 2017 07:30 AM PST
    Speaker: Daniel Mueller, PhD
  • FEB 23, 2017 10:30 AM PST
    Speaker: Erica Ramos, MS, CGC
  • FEB 23, 2017 12:00 PM PST
    Speaker: James Prudent, PhD
  • How Advancements are Shaping Precision Medicine
  • FEB 22, 2017 06:00 AM PST
    Speaker: David Smith, PhD
  • FEB 22, 2017 09:00 AM PST
    Speaker: Ruth Luna, PhD, MB (ASCP) CM
  • FEB 22, 2017 12:00 PM PST
    Speaker: Dexter Hadley, MD, PhD
  • FEB 22, 2017 01:30 PM PST
    Speaker: Sami Amr, PhD
  • FEB 23, 2017 06:00 AM PST
    Speaker: Michael Nall
  • FEB 23, 2017 09:00 AM PST
    Speaker: John Ryals, PhD
  • FEB 23, 2017 12:00 PM PST
    Speaker: Giacinto Scoles, PhD
  • FEB 23, 2017 01:30 PM PST
    Speaker: Nathan Price, PhD
  • Precision Medicine Initiative
  • FEB 22, 2017 07:30 AM PST
    Speaker: Laura Koontz, PhD
  • Precision Medicine for Drug Development
  • FEB 22, 2017 10:30 AM PST
    Speaker: Matt Nelson, PhD
  • Precision Medicine Issues and Challenges
  • FEB 22, 2017 10:30 AM PST
    Salim Essakali
    Associate Director, NGS
    Yi Kong, Ph.D.
    Product Director, QIAGEN
  • FEB 22, 2017 12:00 PM PST
    Speaker: Carl Simon, PhD
  • FEB 23, 2017 06:00 AM PST
    Speaker: Matt Klusas
  • FEB 23, 2017 12:00 PM PST
    Speaker: Marty Tenenbaum, PhD
Posters

 

POSTER SUBMISSION GUIDELINES

Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer reviewed. Submission is free.

 

SUBMIT YOUR ABSTRACT

Enter the following information to this Submission Form:

  • Poster Title
  • Your Name
  • Your Institution
  • Your Email
  • Abstract describing the poster

 

All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

 

If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster.  LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

 

Questions? Email Posters@LabRoots.com

LabRoots Policy

Speakers

  • Laura Koontz, PhD
    Personalized Medicine Staff at the Food and Drug Administration in the Center for Devices and Radiological Health
    Biography
      Laura M. Koontz, PhD, is a member of the Personalized Medicine Staff at the Food and Drug Administration in the Center for Devices and Radiological Health. Prior to joining the FDA, she was the Director of Policy for the Ovarian Cancer National Alliance, where she oversaw Congressional and regulatory policy, including issues pertaining to use and regulation of genetic technologies. Prior to that, she was an ASHG-NHGRI Genetics and Public Policy Fellow from 2012-2013 and worked in the House of Representatives on issues related to genetic testing and genetic nondiscrimination. Dr. Koontz holds a PhD in Biochemistry, Cellular and Molecular Biology from the Johns Hopkins University School of Medicine.
    • Daniel Mueller, PhD
      Head of the Pharmacogenetics Research Clinic at the Campbell Family Mental Health Research Institute at CAMH, and Associate Professor in the Department of Psychiatry at the University of Toro
      Biography
        Dr. Mueller earned his MD at the University of Bonn (Germany) and completed his residency training in Psychiatry at the Charité University Clinic in Berlin. In 2008, he has been appointed at the University of Toronto (Department of Psychiatry), and as Clinician Scientist at CAMH. At the same time, he became Head of the Pharmacogenetics Research Clinic at CAMH which is one of the first of its kind worldwide to develop clinical implementation strategies (e.g., Müller DJ et al., 2013; PMID:24151801). Dr. Mueller's overall research goals are to investigate genetic causes of response and side effects to psychiatric medications. This line of research aims to significantly improve treatment of psychiatric conditions and to lessen the burden of medication side effects and to avoid negative drug-drug interactions. In addition, he is actively involved in developing pharmacogenetic guidelines for physicians and patients and is affiliated with the Clinical Pharmacogenetics Implementation Consortium (Caudle et al., 2014; PMID: 24479687). For more information, visit www.pharmacogenetics.ca For a complete publication record, see: https://scholar.google.de/citations?user=lnbto4AAAAAJ&hl=de
      • Carl Simon, PhD
        Biologist, Biosystems & Biomaterials Division
        Biography
          Dr. Simon is a biologist in the Biomaterials Group at the National Institute of Standards and Technology. We aim to develop reliable tools and standards for measuring the properties of cells, biomaterials, scaffolds and tissue-engineered constructs. As regenerative medicine moves from a research endeavor to a viable industry that benefits patients and U.S. commerce, reliable methods for assessing product consistency and quality are required. In one of our projects, we are working with Kapil Bharti (NIH) to establish simple, robust methods for characterizing tissue-engineered retinal pigment epithelium for use in a clinical trial to treat age-related macular degeneration. In another project, we are working with Pamela Robey (NIH) to improve sampling in measurements of osteogenesis induced by stem cell/scaffold formulations in an ectopic bone mouse model. We also work with computer scientists to develop image analysis and bioinformatics methods for assessing the physical properties of 3D tissue scaffolds and how they influence cell function. Dr. Simon is Chair of ASTM Committee F04.43 "Cells and Tissue-Engineered Constructs" where documentary standards are being developed to support the development of tissue-engineered medical products. He earned a B.S. in Biology from Bucknell University and a Ph.D. in Biochemistry from University of Virginia where his thesis focused on signal transduction during human platelet aggregation. He trained as a post-doctoral fellow in NIST Polymers Division and became a staff scientist at NIST in 2003. Dr. Simon is active in the Society for Biomaterials, ISO, TERMIS and Phacilitate, and is on the editorial board for "Biomaterials" and "Journal of Biomedical Materials Research Part B - Applied Biomaterials".
        • David Smith, PhD
          Professor and Consultant at Mayo Clinic
          Biography
            David I Smith received his B.S. in Mathematics and Molecular Biology from the University of Wisconsin in Madison. He then received his Ph.D. for the Department of Biochemistry also at the University of Wisconsin in Madison. After several postdoctoral positions he got his first academic appointment at Wayne State University. In 1996 he joined the Mayo Clinic in the Department of Laboratory Medicine and Pathology as Professor and Consultant. He was also appointed as the head of the Cancer Genetics Program for the Mayo Clinic Cancer Center. His research focuses on the role that the common fragile sties play in cancer development. His laboratory also works on the various roles that human papillomavirus plays in the development of different cancers. Dr. Smith is also the Chairman of the Technology Assessment Group for the Mayo Clinic Center for Individualized Medicine. The responsibility of this group is to evaluate new technologies for their potential impact on research and its' clinical translation. His laboratory utilizes next generation sequencing to characterize the molecular alterations that occur during the development of cancer. They also have been using the powerful technique of mate-pair next generation sequencing (MP-Seq) to characterize the physical status of HPV in different HPV-driven cancers.
          • Marty Tenenbaum, PhD
            Founder and Chairman at Cancer Commons
            Biography
              Dr. Jay M. ("Marty") Tenenbaum, a world-renowned Internet commerce pioneer and visionary, founded CommerceNet (1994) to accelerate business use of the Internet. While at CommerceNet, he co-founded Veo Systems (1997), the company that pioneered the use of XML for automating business-to-business transactions. When Commerce One acquired Veo Systems in January 1999, Dr. Tenenbaum became chief scientist and was instrumental in shaping the company's business and technology strategies for the Global Trading Web. Post Commerce One, Dr. Tenenbaum was an officer and director of Webify Solutions (sold to IBM in 2006) and Medstory (sold to Microsoft in 2007). Currently, his focus is on transforming healthcare and accelerating therapy development through collaborative e-science. Towards that end, he founded CollabRx, which builds "virtual biotechs" to help slash the time, cost, and risk of developing new therapies." Prior to CommerceNet, he was founder and CEO of Enterprise Integration Technologies, the first company to conduct a commercial Internet transaction (1992), secure Web transaction (1993), and Internet auction (1993). Earlier in his career, Dr. Tenenbaum was also a prominent AI researcher, and led AI research groups at SRI International and Schlumberger Ltd. Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, and a former consulting professor of Computer Science at Stanford. He currently serves as a director of Efficient Finance, Patients Like Me, and the Public Library of Science, and is a consulting professor of Information Technology at Carnegie Mellon's new West coast campus. Dr. Tenenbaum holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a Ph.D. from Stanford.
            • Erica Ramos, MS, CGC
              Clinical Head, Healthy Genome Initiatives, Staff Genetic Counselor, Applied Genomics
              Biography
                Erica Ramos, MS, LCGC is the Clinical Head for Illumina's "Healthy Genome Initiatives" team and President-Elect for the National Society of Genetic Counselors, the leading professional organization for genetic counselors more than 3500 members strong. After 11 years in patient care, Ms. Ramos joined Illumina in the Clinical Services Laboratory, where she managed the clinical group that implemented interpretation and reporting processes for clinical whole genome sequencing (cWGS). Currently, she focuses on advancing the use of cWGS by providing access and education to healthy individuals through the Understand Your Genome program, MyGenome visualization software and other collaborations. Her focus on education extends to genetic counseling students and she is an Adjunct Professor in the Genetic Counseling Department at Augustana University. She also tweets from @ERamosSD about genomics and genetic counseling, music, travel and other interests.
              • James Prudent, PhD
                President and Chief Executive Officer Centrose
                Biography
                  Currently, Dr James Prudent serves as the Chief Executive Officer and Chairman of the Board at CENTROSE, a biotechnology company focused on developing precision therapies for diseases with high unmet need. While exploring interesting natural products, Dr. Prudent and his colleagues discovered that the "all powerful" Na,K-ATPase was interacting with multiple proteins at the cell surface. The biology of the various interacting proteins indicated an evolutionary pattern of energy regulation coupled to growth, motility, and survival. This discovery led to the invention of EDC Technology which allows for the unprecedented precise delivery of drugs. Currently the company has discovered multiple EDCs for cancer and autoimmune disease. Prior to CENTROSE, Dr. Prudent served as Chief Science Officer and Board Member at EraGen Biosciences (now Luminex) where he invented GENE-CODE and MULTI-CODE, technologies that incorporate an expanded genetic code into real-time and multiplexed diagnostic assays. Before EraGen, Dr. Prudent invented Invader Technology while at Third Wave (now Hologic). Invader is complimentary to PCR but does not amplify DNA; making Invader more accurate and easier to use. Today, Invader is being used by Hologic and Exact Sciences in their diagnostic products. Prior to Third Wave, Dr. Prudent received his Ph.D. in Chemistry at the UC - Berkeley under the direction of Professor Peter G. Schultz and his B.S. in Bacteriology and Medical Microbiology at the University of Wisconsin - Madison. He has over 100 publications, patents and patent applications. He is a recipient of the Frost and Sullivan Product of the Year Award and Biotechnology Industry Organization Innovation Award.
                • Dexter Hadley, MD, PhD
                  Assistant Professor of Pediatrics Institute for Computational Health Sciences University of California, San Francisco
                  Biography
                    Dr. Hadley's expertise is in translating big data into precision medicine and digital health. His work has resulted in an ongoing precision medicine clinical trial for ADHD (ClinicalTrials.gov Identifier: NCT02286817) for a first-in-class, non-stimulant neuromodulator to be targeted across the neuropsychiatric disease spectrum. His laboratory was recently funded by the NIH Big Data to Knowledge initiative to integrate multiple large-scale open databases to allow cross platform computational analyzes powerful enough to discover the functional genes and their related biological pathways that are defective in disease. He received the inaugural UCSF Marcus Award for Precision Medicine to develop a digital health initiative to use smartphones to screen for skin cancer and reduce the mortality of melanoma. In general, the end point of his work is rapid proofs of concept clinical trials in humans that translate into better patient outcomes and reduced morbidity and mortality across the spectrum of disease.
                  • Sami Amr, PhD
                    Director of the Translational Genomics Core of Partners HealthCare Personalized Medicine, Harvard Medical School
                    Biography
                      Sami Amr is the Director of the Translational Genomics Core of Partners HealthCare Personalized Medicine where he feels privileged to work with basic and translational researchers across Partners Healthcare to identify DNA, RNA, and methylation markers and signatures of disease that can help de-convolute underlying mechanisms of pathogenesis as well as be leveraged in diagnostic and clinical assays.
                    • Ruth Luna, PhD, MB (ASCP) CM
                      Director, Medical Metagenomics Texas Children's Microbiome Center Texas Children's Hospital Assistant Professor Baylor College of Medicine
                      Biography
                        Dr. Ruth Ann Luna serves as Assistant Professor in the Department of Pathology & Immunology of Baylor College of Medicine and as Director of Medical Metagenomics within the Texas Children's Microbiome Center at Texas Children's Hospital. Dr. Luna directs the next-generation sequencing efforts of the Texas Children's Microbiome Center and focuses on multi-omic profiling in a variety of body sites and disease populations. Dr. Luna is a member of the Institutional Review Board of Baylor College of Medicine and is active in clinical research. As principal investigator of two ongoing studies, she is exploring the gastrointestinal and neurobehavioral aspects of children diagnosed with autism spectrum disorder (ASD), with specific emphases on the gut microbiome and metabolome, as well as the impact of antibiotic treatment on the core symptoms of ASD.
                      • Marc Williams, MD
                        Director, Genomic Medicine Institute Geisinger Health System
                        Biography
                          My primary interest has been to study the impact of implementing genetics, genomics and family history in routine clinical care. Successful implementation requires the application of many disparate elements including technology assessment, modeling and decision analysis, the science of behavioral change, quality improvement, knowledge management, informatics, health care economics and patient-centered outcomes all of which are components of the emerging discipline of implementation science. I am also very interested in defining the value proposition of new genomic technologies with value being simplistically represented as outcomes/cost. My research to date has examined the impact of family history on provider experience; the role of informatics to provide point-of-care, "just-in-time" education resources and passive decision support to clinicians regarding genetic topics; impact of tumor-based screening for Lynch syndrome (including extensive modeling to optimize the efficiency of the program); use of query tools to obtain information on genetic conditions from electronic data warehouses; and application of the tools of quality improvement to facilitate implementation of evidence-based best practices in genetics and genomics. I am now beginning to explore how we can get information from patients about their preferences including an assessment of the patient's location on the State of Change continuum and use those preferences to reconcile priorities regarding preventive and therapeutic interventions with the patient's provider to see if that will improve satisfaction for both and increase compliance with recommendations leading to measurable improvement in outcomes and improved value.
                        • Matt Nelson, PhD
                          Head, Genetics at GlaxoSmithKline
                          Biography
                            Matt Nelson is the head of Genetics at GSK, working in Philadelphia, PA, leading a group of scientists to bring genetic evidence into both drug discovery and drug development decisions. Research activities of interest include investigating the role of growing body genome-wide association studies to inform drug target selection and validation, improving pharmacogenetics experiment design and developing methods and strategies for drawing inferences from both small- and large-scale genetic association studies. Other recent activities include analysis of deep resequence data for target validation, development of the POPRES genetic resource for pharmacogenetics research and co-chair of the scientific management committee of the cross-industry International Serious Adverse Event Consortium (iSAEC). Matt's path to research in the pharmaceutical industry began at the University of Michigan, where he received degrees in statistics and human genetics with an emphasis on novel combinatorial strategies for identifying gene-by-gene interaction. Upon graduation, he worked with start-up biopharmaceutical company Esperion Therapeutics for three years. At Esperion, his activities included cheminformatics, preclinical and clinical study design and analysis, development of online analysis and reporting tools, and leading the information systems group. Matt joined Sequenom, a San Diego-based biotechnology company, in early 2002 as director of biostatistics, where he was involved in some of the earliest attempts at genome-wide association studies. Matt has been with GSK since 2005 with prior roles as researcher and head of Statistical Genetics.
                          • John Ryals, PhD
                            President and Chief Executive Officer, Metabolon
                            Biography
                              Dr. John Ryals co-founded Metabolon, Inc. in 2002 and serves as president and CEO. Metabolon is a pioneer and leader in the field of metabolomics and its use in precision medicine and human health. Prior to Metabolon, he was a co-founder, CEO and president of Paradigm Genetics, Inc., a publicly traded agricultural biotechnology company focused on industrializing the process of gene function discovery. Dr. Ryals has 30 years' experience in the biotechnology industry, including senior research positions at Novartis and Ciba-Geigy. He currently serves on the board of directors at AgBiome, a provider of early-stage R&D for agriculture, and the advisory board of the College of Agriculture and Life Sciences at North Carolina State University. He earned a B.A. in biology and chemistry from the University of North Texas and M.S. and Ph.D. degrees in molecular biology from the University of Texas at Dallas.
                            • Michael Nall
                              President and CEO at Biocept
                              Biography
                                Mr. Nall has over 25 years of healthcare sales and marketing experience, most recently serving at Clarient Diagnostic Services, Inc. in positions of increasing responsibility from 2002 through August 2013, with his last position being General Manager, North American Sales and Marketing. While at Clarient, Mr. Nall was also responsible for leading the team assimilating Clarient into GE Healthcare after Clarient was acquired in 2010. From 1988 until joining Clarient, Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including Impath, American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems. Mr. Nall received a Bachelor of Science degree in Business Administration from Central Missouri State University (now known as the University of Central Missouri).
                              • Nathan Price, PhD
                                Professor and Associate Director, Institute for Systems Biology
                                Biography
                                  Dr. Price is Professor & Associate Director of the Institute for Systems Biology (ISB) in Seattle, WA. He is also Affiliate Faculty in the Departments of Bioengineering, Computer Science & Engineering, and Molecular & Cellular Biology at the University of Washington. He is Co-Founder and on the Board of Directors of Arivale ("Your Scientific Path to Wellness"), which was recently named as Geekwire's 2016 "Startup of the Year." Nathan has won numerous awards for his scientific work, including a Howard Temin Pathway to Independence Award from the National Institutes of Health, a National Science Foundation CAREER award, a young investigator award from the Roy J. Carver Charitable Trust, and he was named as one of the inaugural "Tomorrow's PIs" by Genome Technology and as a Camille Dreyfus Teacher-Scholar. Most recently, he received the 2016 Grace A. Goldsmith Award from the American College of Nutrition, given to a scientist under the age of 50 for significant achievements in the field of nutrition for his work in scientific wellness. Dr. Price has published over 100 peer-reviewed scientific publications and serves on editorial boards for many leading scientific journals including Science Translational Medicine and Cell Systems. Dr. Price served on the National Academy of Medicine committee to review omics-based tests to predict clinical outcome in clinical trials. Dr. Price also serves on scientific advisory boards for a number of companies and institutes including Habit (a personalized nutrition company), Trelys (a metabolic engineering company),Cleveland Clinic's Center for Functional Medicine, the Novo Nordisk Foundation Center for Biosustainability, the P4 Medicine Institute, the University of Washington's Public Health Genomics Institute, the UW Multidisciplinary Learning Disability Center, and the DOE ENIGMA program at UC Berkeley/LBNL/MIT. He is also a fellow of the European Society of Preventive Medicine.
                                • Giacinto Scoles, PhD
                                  Donner Professor of Science and Professor of Chemistry, Emeritus
                                  Biography
                                    Giacinto Scoles (b. 1935, married to Lim Giok Lan since 1964) is Donner professor of Science, Emeritus at Princeton University, distinguished adjoint professor in the Departments of Physics and Biology at Temple University, and distinguished scientist at Synchrotron Elettra in Trieste. He is presently senior grantee of the ERC in the faculty of Medicine at the University of Udine (Italy). His career has spanned an unusually long length of time and an equally unusually broad range of subjects. He has developed instrumentation in mass spectroscopy, gas viscosimetry, crossed molecular beam scattering, clusters formation and spectroscopy, surface monolayer, grazing incidence X-ray scattering, super-fluid helium droplets; manipulation of bio-molecules, bio-molecular interaction at the nano scale and medical nano diagnostics. He and a group of collaborators have recently patented a method to count circulating tumor cells based on the measurement of the metabolism of every cell isolated into a droplet of blood of several picoliters. When the droplet results to become acid, that indicates the presence of the cancer cells. He has received several recognitions: the Herschbach prize (2013); the gold medal of honor of the Italian Chemical Society; the Ben Franklin Medal for Physics (2006) 2 Honorary doctorates (1997 and 2000) the Debye prize of the ACS, the Plyler prize of the APS and the Lippincott Award of the OSA. He is a Fellow of the APS, OSA and of the ROYAL Society of the UK and of the Royal Science Academy of the Netherlands (KNAW). He has published about 300 papers in peer reviewed journals, and has been quoted by his colleagues approximately 19.000 times, his H-index is 73, while the i10-index is 224. He has supervised about a hundred PhD students, an unusually high percentage of which now covers positions of responsibility in Academia and research.
                                  • Matt Klusas
                                    Chief Commercial Officer, Omniseq
                                    Biography
                                      Matt Klusas serves as Chief Commercial Officer at OmniSeq. He leads the OmniSeq sales, marketing, business development, and customer service functions. Prior to joining OmniSeq, Matt was most recently at Thermo Fisher Scientific, where he led a business focusing on large scale deployments of genetic analysis technologies, including next generation DNA sequencing, Capillary Electrophoresis sequencing, qPCR, and other technologies. Prior to Thermo Fisher Scientific, Matt held management roles at the American Type Culture Collection (ATCC), Life Technologies, and McKinsey & Co. Matt is published in the Journal of Commercial Biotechnology, the McKinsey Quarterly, and the Credit Union Journal. In 2015, Illinois State University selected him the Young Alumni of the Year. He received an MSc in Economic History from the London School of Economics and a BS in Communication from the Illinois State University. He also studied at Magdalen College, University of Oxford.
                                    • Yi Kong, Ph.D.
                                      Product Director, QIAGEN
                                      Biography
                                        Yi is currently a Product Director at QIAGEN, responsible for content and application development of Cancer Molecular Research and Diagnostics. She led efforts to develop and commercialize the GeneReader NGS System. She has years of experience working in the diagnostic and pharmaceutical industries, in various development, product management, marketing and strategic planning roles. She started her career as a biomedical scientist, having published many peer-reviewed articles and a diagnostics patent.
                                      • Salim Essakali
                                        Associate Director, NGS
                                        Biography
                                          Salim Essakali studied biology at Heinrich-Heine University, Düsseldorf, Germany and specialized in biomedicine. He conducted his Master's thesis at Peter MacCallum Cancer Center in Melbourne, Australia analyzing gene expression profiles in chronic lymphocytic leukemia. In October 2007, he joined the Global Product Management Team at QIAGEN in Hilden, Germany and has been responsible for managing multiple automated platforms and bioinformatics solutions
                                        Sponsored By

                                        For information on becoming a sponsor or exhibitor, please click here.


                                        Continuing Education (CME/CE/CEU) Credits

                                        The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here

                                        The presentational method for this activity will be Lecture with an opportunity for real-time question and answer periods for the live activity, and on demand access of the presentation for the enduring material activity. Both the internet live course and the internet activity enduring material is geared towards physicians, research scientists, principal investigators, lab directors, clinicians, and other medical professionals. This activity will encompass the following desirable physician attributes:  Patient Care & Procedural Skills, Medical Knowledge, Professionalism, Interpersonal & Communication Skills, Practice-Based Learning & Improvement, and Systems-Based Practice.

                                        Desired Outcomes

                                        At the end of the activity, participants should be able to:

                                        • Integrate approaches outlined within the range of activities that make up the Precision Medicine Initiative, including biobanking, clinical genome sequencing, data analytics, consumer genetics, rational drug development, etc.
                                        • Identify clinical implementations of precision medicine relevant to the learner’s practice
                                        • Recognize how advancements are shaping precision medicine
                                        • Recognize how precision medicine is impacting drug development
                                        • Navigate precision medicine issues and challenges as it relates to prevention, diagnosis, and treatment
                                        • Eliminate disparities and achieve impartial treatment through enhanced communication and cultural competency, which can reduce the impact of bias and stereotyping in precision medicine

                                        This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Institute for Medical Quality/California Medical Association (IMQ/CMA) through the joint providership of CME Consultants and LabRoots. CME Consultants is accredited by the IMQ/CMA to provide continuing medical education for physicians.

                                        CME Consultants designated this internet live course and this internet activity enduring material for a maximum of 6.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

                                        Enduring Material release date: 2/24/17

                                        Enduring Material Termination date: 8/24/17

                                        In accordance with the Americans with Disability Act (ADA), please contact LabRoots at ce@labroots.com should you require special assistance.


                                        Committee

                                        To download the Program Committee brochure here.


                                        • Sarah Elsea, PhD

                                          Dr. Sarah H. Elsea is an Associate Professor of Molecular and Human Genetics at Baylor College of Medicine and is Senior Division Director of Biochemical Genetics at Baylor Genetics. Dr. Elsea earned a B.S. in chemistry from Missouri State University and Ph.D. in biochemistry ...

                                          See more See less
                                        • Iya Khalil, PhD

                                          Iya Khalil, co-founder and executive vice president of GNS, has promoted use of the Cambridge, MA-based company's technology in the biopharma industry. One of the inventors of the company's computational platform, her work has helped major players such as Biogen Idec and Johnson ...

                                          See more See less
                                        • Tatjana Matejic, PhD, D(ABMLI)

                                        • Giacinto Scoles, PhD

                                          Giacinto Scoles (b. 1935, married to Lim Giok Lan since 1964) is Donner professor of Science, Emeritus at Princeton University, distinguished adjoint professor in the Departments of Physics and Biology at Temple University, and distinguished scientist at Synchrotron Elettra in ...

                                          See more See less
                                        Help

                                        General LabRoots Questions

                                        For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                                        Contact us

                                        Virtual Events and Webinars

                                        Supported Configurations

                                        • Operating System Internet Explorer Firefox Chrome Safari
                                          Vista IE8+ FF10+ Chrome15+
                                          Windows 7 IE8+ FF10+ Chrome15+
                                          Windows 8 IE10 FF10+ Chrome15+
                                          Mac OS X   FF10+ Chrome15+ Safari5.1+
                                        • Cookie settings: session cookies enabled
                                        • Browser configuration must have JavaScript enabled
                                        • Adobe Flash player 10.2 or later

                                        To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                        Internet Connection

                                        • A minimum of 100Kbps is recommended for audio-only events
                                        • A minimum of 300Kbps is recommended for speaker on-video events

                                        Computer Equipment

                                        • Screen Resolution: Minimum 1024x768
                                        • Video Card: 65,000 colors minimum
                                        • Sound card and speakers (or headphones) for hearing webcast in full format
                                        • Audio Card: 16-bit minimum
                                        • RAM: 512MB of free RAM

                                        Firewall Protocol

                                        • HTTP on port 80 or HTTPS on port 443
                                        • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                        • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                        Work-At-Home Attendees

                                        • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                        For A Seamless Experience

                                        When using a mobile device, FREE Mobile Apps are available:

                                        - For viewing Webinars:

                                        - For viewing Virtual Events

                                        Attendee Guide

                                        • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                        Virtual Event and Webinar Support:

                                        Continuing Education (CME/CE) Support

                                        Loading Comments...
                                        Show Resources